17 results about "Alkalinizing agent" patented technology

The application belongs to the technical field of starch chemical modification, and particularly relates to a preparation method of acetylated distarch phosphate. The method comprises the following steps: mixing starch with a deep eutectic solvent composed of choline chloride, glycerol and a small amount of water, adding a phosphate crosslinking agent and a delayed-release alkalizing agent for crosslinking reaction after pH adjustment, performing acetylation reaction by adding acetic anhydride or vinyl acetate after cleaning by alcohol solvent replacement, and finally obtaining the product through neutralization, washing, dehydration and drying. The process utilizes the deep eutectic solvent to control water activity and particle structure, and combines the slow-release alkali source to maintain a stable reaction environment, so that the crosslinking and acetylation are uniformly carried out, and the side reactions and residual salt load are effectively reduced. The obtained acetylated distarch phosphate has stable substitution degree, uniform particle structure and excellent performance in freeze-thaw stability, and is suitable for multiple fields such as papermaking, textile and oil field additives.

The present invention relates to an oral pharmaceutical composition comprises semaglutide, SNAC (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), one or more alkalizing agent and one or more pharmaceutically acceptable excipients.

The present invention provides a pharmaceutical composition for treating an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, the pharmaceutical composition comprising an alkalizing agent. By administering this pharmaceutical composition, it is possible to treat an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, in particular, a chemotherapeutic agent for cancer. The present invention also provides an anticancer pharmaceutical composition that contains an alkalizing agent and a chemotherapeutic agent for cancer and that is designed to suppress an acute-phase peripheral neuropathy induced by the chemotherapeutic agent or to suppress worsening of symptoms caused by the peripheral neuropathy. By administering this pharmaceutical composition, it is possible to provide a cancer treatment in which an acute-phase peripheral neuropathy or worsening of symptoms caused by the peripheral neuropathy is suppressed.

A composition for treating dentin hypersensitivity, comprising: a first component comprising: (i) a first rheology modifying polymer; (ii) a calcium ion source; (iii) a positively charged basic amino acid; and (iv) an acidifying agent, wherein the first component has a pH in the range of about 2.0 to about 7.0; a second component comprising: (i) a second rheology modifying polymer; (ii) a phosphate ion source; and (iii) an alkalizing agent, wherein the second component has a pH in the range of about 7.0 to about 14.0; wherein the first component and the second component are combined into a mixture such that a cationic amorphous calcium phosphate gel composition is created instantly when the pH of the mixture reaches a pH range of about 7.0 to about 9.5.

A hydraulic binder including (in % by dry weight); A. at least 50 of at least one ground and granulated blast-furnace slag; B. more than 5 of at least one calcium aluminate cement and / or of at least one calcium sulfoaluminate cement; C. more than 5 of at least one source of sulfate ions; D. between 1 and 5 of Ca(OH)2 and / or Portland cement; E. between 0.01 and 1 of at least one alkali metal carbonate; F. and at least one alkalifying reagent consisting of at least one alkali metal carbonate and / or bicarbonate, different from E; under the following conditions: (i) amount of C allows sulfate ions of C to react with B and A; (ii) the amount of F sufficiently causes a reaction with D in water resulting in a wet formulation with a pH not less than 12, for a water-to-mortar mixing rate between 10 and 35% by weight.

The invention provides a rapid evaluation method for the chain segment characteristics of ethyl cellulose, which comprises the following steps: preparing an EC emulsion from an ethyl cellulose sample to be detected, and determining the chain segment characteristics of ethyl cellulose by measuring the parameters of the EC emulsion. The detection parameters of the EC emulsion product comprise the ethyoxyl content, the emulsion peak number, the average particle size and the particle size distribution. The preparation method of the EC emulsion comprises the following steps: S1, crushing and sieving an ethyl cellulose sample for later use; s2, placing the ethyl cellulose undersize product in a reactor, sequentially adding a plasticizer and a solvent into the reactor while stirring, and dispersing to obtain an oil-phase intermediate; and S3, adding an emulsifier and an alkalizer into the oil-phase intermediate, and adding the oil-phase intermediate into distilled water for multiple times under high-shear dispersion to obtain the EC emulsion to be detected. According to the method, the emulsification technology is applied to determination of EC chain segment distribution characteristics for the first time, the method has good applicability and universality, the whole detection process is efficient and rapid, data reliability is enhanced, and application predictability is accurate.

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75% ± 2% by weight cyclobenzaprine HCl and 25% ± 2% by weight β‑mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

The application provides a nano cerium dioxide-based fuel additive and a preparation method and application thereof. The preparation method of the nano cerium dioxide-based fuel additive comprises the following steps: mixing a ligand, a dispersing agent, a dissolving oil and an oil phase auxiliary agent to obtain an oil phase; mixing cerium halide, an aqueous phase solvent, an oxidizing agent and an alkalizing agent to obtain an aqueous phase; and reacting the oil phase and the aqueous phase by using a supergravity reaction method to obtain the nano cerium dioxide-based fuel additive. The nano cerium dioxide-based fuel additive can be stably dispersed in fuel.

This invention relates to the field of biomedical technology, and more particularly to a fenelazol microsphere, its preparation method, and capsules. This invention optimizes the formulation of the original fenelazol tablets, using blank pellet cores as a carrier, sodium carbonate as an alkalizing agent, and sulfobutyl-β-cyclodextrin as an excipient to prepare fenelazol microsphere capsules. Experiments show that these microspheres have excellent solubility in gastric acid, are pH-independent, and exhibit high long-term storage stability. This invention simplifies the production process, has good process stability, low production costs, and is suitable for large-scale production.

The application relates to a treatment method of hydrometallurgical raffinate, which comprises the following steps: performing a fractional co-precipitation reaction on the raffinate by using characteristic seeds in the presence of an alkalizing agent until the heavy metal content in the raffinate is less than 10 mg / L and the COD is less than 300 mg / L. The treatment method provided by the application recycles the characteristic seeds as renewable resources, can realize synchronous removal of organic matters and heavy metal ions in the raffinate wastewater and resource recovery, the COD of the raffinate effluent is less than 300 mg / L, the concentration of heavy metal ions is less than 10 mg / L, the heavy metal recovery rate is more than 98%, the hydraulic retention time is short, the turbidity of the effluent is small, no sludge is produced, no secondary pollution is caused, and the cost is effectively reduced.

The present invention relates to a process and mixture for the safe dosing of a sulfidizing agent in a mineral flotation process that comprises the prior preparation of a mixture of sulfidizing agent with at least one alkalizing agent. In this way, the production of hydrogen sulfide is prevented, allowing the mixture to be safely used in mining operations located in enclosed places such as caves or in operations close to populated areas.

The utility model relates to the technical field of online sodium degree instruments, and particularly discloses an online sodium degree analyzer pretreatment device which comprises a box body, an online sodium degree instrument, a basifier bottle, a measuring cell and a Venturi tube, and the online sodium degree instrument, the basifier bottle, the measuring cell and the Venturi tube are arranged in the box body, and a detection electrode used for being inserted into the measuring cell is arranged on the online sodium degree instrument; one end of the venturi tube is used for being connected with a sample water feeding tube, the other end of the venturi tube is connected with the measuring cell through a water outlet tube, the inner diameter of the venturi tube is large at the two ends and small in the middle, and the alkalizer bottle is communicated with the position, with the smaller inner diameter, of the venturi tube through a feeding tube. The diisopropylamine adding device has the effect of solving the problems that frequent maintenance and repair are needed when an external pump is adopted for adding diisopropylamine, and the use cost is increased.

To provide a bactericidal cleaning agent and a bactericidal cleaning kit for hemodialysis machines that meet the dialysis wastewater pH standard (greater than 5.00 and less than 9.00) and have calcium carbonate removal ability and bactericidal effect equivalent to or better than that of strongly acidic peracetic acid preparations. [Solution] The cleaning agent has a composition that includes a peroxide, a specific chelating agent, and optionally a specific alkalizing agent.

The application discloses a compound tablet for treating hypertension, which comprises telmisartan, benzenesulfonic acid amlodipine, an alkalizing agent, a binder, a filling agent, a lubricant and a flow aid, and is characterized in that: the benzenesulfonic acid amlodipine is externally attached with a coating film; the coating material of the coating film is a gastric soluble coating material stable under an alkaline condition; and the weight ratio of the coating material to the benzenesulfonic acid amlodipine is (1-2.5): 1. The coating material is one or more of hydroxypropyl methyl cellulose, Eudragit E series and hydroxypropyl cellulose. The application provides a telmisartan amlodipine tablet with high stability and outstanding dissolution performance.

A multi-component packaging unit (kit-of-parts) for the reductive decolorization of dyed keratinous fibers, which is packaged separately, comprises: a container (A) containing a cosmetic agent (a) and a container (B) containing a cosmetic agent (b), wherein the agent (a) in container (A)(a1) comprises one or more sulfinic acid derivatives from the group consisting of: (H2N)(NH)C(SO2H) formamidine sulfinic acid, HN(CH2SO2Na)2, disodium [(sulfinatomethyl)amino]methanesulfinate, HN(CH2SO2K)2, dipotassium [(sulfinatomethyl)amino]methanesulfinate, HN(CH2SO2H)2, [(sulfinomethyl)amino]methanesulfinic acid, N(CH2SO2Na)3, trisodium [bis(sulfinatomethyl)amino]methanesulfinate- N(CH2SO2K)3, tripotassium [bis(sulfinatomethyl)amino]methanesulfinate- N(CH2SO2H)3, [bis(sulfinomethyl)amino]methanesulfinic acid- H2NCH(CH3)SO2Na, sodium 1-aminoethane-1-sulfinate- H2NCH(CH3)SO2K, potassium 1-aminoethane-1-sulfinate- H2NCH(CH3)SO2H, 1-aminoethane-1-sulfinic acid,- HN(CH(CH3)SO2Na)2,Disodium 1-[(1-sulfinatoethyl)amino]ethane-1-sulfinate- HN(CH(CH3)SO2K)2, Dipotassium 1-[(1-sulfinatoethyl)amino]ethane-1-sulfinate- HN(CH(CH3)SO2H)2, 1-[(1-sulfinoethyl)amino]ethane-1-sulfinic acid- N(CH(CH3)SO2Na)3, Trisodium 1-[bis(1-sulfinatoethyl)amino]ethane-1-sulfinate- N(CH(CH3)SO2K)3, Tripotassium 1-[bis(1-sulfinatoethyl)amino]ethane-1-sulfinate and / or- N(CH(CH3)SO2H)3, 1-[bis(1-sulfinoethyl)amino]ethane-1-sulfinic acid contains,(a2) one or more fatty components from the group of C12-C30 fatty alcohols, C12-C30 fatty acid triglycerides, C12-C30 fatty acid monoglycerides, C12-C30 fatty acid diglycerides, C12-C30 fatty acid esters, hydrocarbons and / or silicone oils,(a3) has a water content of not more than 10.0% by weight - based on the total weight of the product (a),- the product (b) in container (B)(b1) has a water content of at least 30.0% by weight - based on the total weight of the product (b),(b2) contains one or more alkalizing agents from the group consisting of ammonia, alkanolamines and / or basic amino acids, and (b3) has a pH of 7.5 to 12.5.

The present invention relates to: a formulation for oral administration, comprising semaglutide and an absorption promoter as active ingredients and optionally further comprising an alkalizing agent; and a preparation method for the formulation. It has been confirmed that sodium caprate exhibits an excellent effect as an absorption promoter for the oral administration of semaglutide, which is a drug, and when the two substances are combined in the form of a single-layer tablet, a bilayer tablet, or a cored tablet, the stability of the formulation, the bioavailability of semaglutide, and the like are significantly increased, and thus it is possible to provide a formulation for oral administration with increased bioavailability and a preparation method for the formulation.

The utility model discloses a multichannel cation bed sodium ion alkalization system, and belongs to the technical field of water quality pretreatment. Comprising a multi-channel sample injection module which comprises at least three independent water sample treatment channels, and each water sample treatment channel is connected with a water inlet of a central pipeline through an electromagnetic valve; the diffusion type alkalization device is connected with the water outlet of the central pipeline and is used for injecting an alkalization agent into the water sample passing through the water sample treatment channel; the detection module is used for collecting water sample data after alkalization treatment; the alarm module is used for giving an alarm in an abnormal state; and the intelligent control system dynamically adjusts the flow of the basifier and controls the alarm module to give an alarm based on comparison of a detection result of the detection module and a preset standard value. According to the utility model, the detection of different water samples can be realized by switching the adopted channels, and the precision is high.